Advertisement

HJLI

Hancock Jaffe Laboratories

Healthcare

Set alert

Price alert · HJLI

All alert types
10.38 0.00 0.00%
As of Oct 1, 2021
10.26 Day range 10.74

52-week range unavailable

Open
10.71
Prev close
10.38
Mkt cap
98.26M
Vol
221.87K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
10.26
High
10.74
Forward P/E
-9.98
Beta
1.54
Short ratio
2.54
Inst. own
23.17%
Dividend
0.00
Ex-div date
Earnings
Nov 16, 2021
50-d avg
9.02
200-d avg
6.95
1y target
26.00

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for HJLI has not been loaded yet. Try again in a moment.

Key statistics

Market cap
98.26M
Enterprise value
48.06M
Trailing P/E
0.00
Forward P/E
-9.98
PEG ratio
0.00
Price / sales
0.00
Price / book
2.16
EPS (TTM)
-2.71
Beta
1.54
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-7.56M
Total cash
41.04M
Total debt
723.55K
Return on equity
-55.76%
Shares outstanding
9.47M
Short % of float
8.37%
50-day average
9.02
200-day average
6.95

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 26.00

Next earnings

Nov 16, 2021

Expected Nov 16, 2021. Consensus EPS estimate -0.34.

Earnings history

Earnings

HJLI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 16, 2021Sep 1, 20210.00———
Aug 11, 2021Jun 1, 20210.00———
May 12, 2021Mar 1, 20210.00———
Nov 17, 2020Sep 1, 20200.00———
Aug 14, 2020Jun 1, 20200.00———

About Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on HJLI — it syncs with the Stock Master app.

Insider holders

HJLI insider holders
InsiderRelationLatest transactionDateShares held
BIODYNE HOLDING, S.A.UnknownSaleAug 20, 20201,405,430
BROENNIMANN BENEDICTOfficerStock Award(Grant)Nov 26, 20180
DUHAY FRANCISDirectorStock Award(Grant)Jul 16, 2020107,228
GRAY ROBERTDirectorStock Award(Grant)Jul 16, 202078,250
JENUSAITIS MATTHEWDirectorStock Award(Grant)Jul 16, 202062,500
SHRIVASTAVA SANJAYDirectorStock Award(Grant)Jul 16, 202097,500

Institution ownership

HJLI institution ownership
Holder% heldSharesValueReported
AIGH Capital Management LLC3.99%346,8852.38MJun 29, 2021
Vanguard Group, Inc. (The)2.98%258,6801.78MJun 29, 2021
Worth Venture Partners, LLC0.95%82,886569.43KJun 29, 2021
Kepos Capital Lp0.82%71,428490.71KJun 29, 2021
Geode Capital Management, LLC0.73%63,753437.98KJun 29, 2021
Blackrock Inc.0.26%22,430154.09KJun 29, 2021

Fund ownership

HJLI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.74%151,1501.04MJun 29, 2021
Vanguard Extended Market Index Fund1.21%104,806720.02KJun 29, 2021
Fidelity Extended Market Index Fund0.47%40,672250.54KJul 30, 2021
iShares Micro Cap ETF0.23%20,366160.48KAug 30, 2021
Fidelity Total Market Index Fund0.12%10,20862.88KJul 30, 2021
Fidelity Series Total Market Index Fund0.07%5,88236.23KJul 30, 2021
Advertisement